Published in
Taylor and Francis Group, OncoImmunology, 2(1), p. 229-231
Links
- ORCID
- Taylor and Francis Group
- [www.ncbi.nlm.nih.gov] | PDF
- [www.researchgate.net] | PDF
- [www.ncbi.nlm.nih.gov] | PDF
- [www.ncbi.nlm.nih.gov] | PDF
- [europepmc.org] | PDF
Tools
IL-33/ST2 axis in innate and acquired immunity to tumors
Journal article published in 2012 by
Ivan P. Jovanovic,
Nada N. Pejnovic 
,
Gordana D. Radosavljevic,
Nebojsa N. Arsenijevic,
Miodrag L. Lukic
,
Gordana D. Radosavljevic,
Nebojsa N. Arsenijevic,
Miodrag L. Lukic
This paper is available in a repository.
Full text: Download
Preprint: archiving forbidden
Published version:
archiving forbidden
Data provided by 
Abstract
Interleukin-33, a ligand for ST2/T1, has an important role in allergy, autoimmunity and inflammation. The role of IL-33/ST2 axis in cancer is not elucidated. Using metastatic breast cancer model we provide evidence that lack of ST2 signaling led to reduced tumor growth and metastasis and enhanced anti-tumor immunity.